ArticleEuropean journal of medical research2025
Aqueous humor cytokine levels in retinal vein occlusion patients with suboptimal response to anti-VEGF therapy and the correlation with OCT imaging biomarkers.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Retinal, Vascular, and Choroidal Remodeling After Non-Reperfused Central Retinal Artery Occlusion: A Longitudinal OCT Study.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo assess the differences in baseline and longitudinal cytokine profiles among super responders, slow responders, and non-responders in patients with retinal vein occlusion-macular edema (RVO-ME) and evaluate the association of cytokines with biomarkers identified on optical coherence tomography (OCT).
methodsForty-four patients with RVO-ME and 37 patients with cataract were enrolled. Aqueous humor samples were collected before the first and second anti-vascular endothelial growth factor (VEGF) injections. The aqueous samples were analyzed for cytokine levels using multiplex immunoassay. OCT-based response categories were defined as super responders, slow responders, and non-responders according to ME resolution. Central retinal thickness (CRT), subretinal fluid (SRF), hyperreflective foci (HRF), disorganization of retinal inner layers (DRIL), and disorganization of retinal outer layers (DROL) were obtained for analysis.
resultsAt baseline, RVO patients exhibited elevated VEGF, placental growth factor (PIGF), angiopoietin-2 (Ang-2), interleukin-6 (IL-6), IL-8, intercellular adhesion molecule-1 (ICAM-1) and monocyte chemoattractant protein-1 (MCP-1) compared with controls (p < 0.01). Super responders showed significantly lower baseline Ang-2 and IL-6 (p = 0.027 and 0.034, respectively) than slow and non-responders. Patients with severe edema and high HRF were likely to have higher levels of IL-6 (p < 0.05). Patients who presented with SRF or DROL at baseline showed higher levels of IL-6 and Ang-2 (p < 0.05). Multivariate linear regression revealed that the presence of SRF was associated with higher baseline Ang-2 (p = 0.029), and high HRF number was associated with higher baseline IL-6 (p = 0.048). After initial injection, non-responders still retained higher Ang-2 and IL-6 concentrations (p = 0.012 and p = 0.040, respectively) than super responders.
conclusionAng-2 and IL-6 expression in aqueous humor were associated with specific OCT features and treatment response in RVO-ME. Lower baseline Ang-2 and IL-6 levels may predict superior anti-VEGF response, while persistently elevated levels were correlated with non-response. TRANSLATIONAL RELEVANCE: Intraocular cytokines were found to be correlated with both the responsiveness to anti-VEGF therapy and OCT imaging biomarkers. This correlation suggested a potential connection to the underlying pathways and their significance in the prognosis of RVO, thereby facilitating personalized anti-VEGF therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.